What is Mounjaro?
An introduction to Mounjaro, the brand name for tirzepatide approved for type 2 diabetes. Learn how this dual GIP/GLP-1 agonist differs from other diabetes medications.
What is Mounjaro?
Mounjaro is the brand name for tirzepatide, a medication FDA-approved for treating type 2 diabetes. It’s manufactured by Eli Lilly and was approved in May 2022. Mounjaro is notable for being the first dual GIP/GLP-1 receptor agonist.
How is Mounjaro Different from Zepbound?
Both contain tirzepatide but are approved for different conditions:
| Feature | Mounjaro | Zepbound |
|---|---|---|
| Approved For | Type 2 diabetes | Weight management |
| Manufacturer | Eli Lilly | Eli Lilly |
| FDA Approval | May 2022 | November 2023 |
| Doses Available | 2.5-15 mg | 2.5-15 mg |
How Does Mounjaro Work?
Mounjaro is unique because it activates two hormone receptors instead of one:
GLP-1 Receptor Activation
- Increases insulin when blood sugar is high
- Slows gastric emptying
- Reduces appetite
GIP Receptor Activation
- Enhances insulin secretion
- May improve fat metabolism
- Complements GLP-1 effects
This dual action is why tirzepatide is called a “twincretin.”
What is Mounjaro Approved For?
FDA-Approved Indication
- Type 2 diabetes — to improve blood sugar control as an adjunct to diet and exercise
Can Be Used
- As monotherapy (alone)
- With other diabetes medications
- With or without metformin
Not Approved For
- Weight management (use Zepbound)
- Type 1 diabetes
- Diabetic ketoacidosis
What Does the Research Show?
The SURPASS clinical trial program demonstrated strong results:
| Trial | Comparison | HbA1c Reduction (15 mg) |
|---|---|---|
| SURPASS-1 | vs placebo | -2.07% |
| SURPASS-2 | vs semaglutide 1 mg | -2.30% vs -1.86% |
| SURPASS-3 | vs insulin degludec | -2.37% vs -1.34% |
Many participants achieved HbA1c levels below 5.7% (non-diabetic range).
Key Facts
| Fact | Detail |
|---|---|
| Administration | Once weekly injection |
| Starting Dose | 2.5 mg (titrated up) |
| Maximum Dose | 15 mg |
| Device | Pre-filled single-dose pen |
Common Side Effects
- Nausea (usually mild and temporary)
- Diarrhea
- Decreased appetite
- Vomiting
- Constipation
Who Should Not Use Mounjaro?
- People with personal or family history of medullary thyroid carcinoma
- People with Multiple Endocrine Neoplasia syndrome type 2
- Those with known hypersensitivity to tirzepatide
This guide is for educational purposes only. Mounjaro is a prescription medication requiring medical supervision.
Sources & Citations
- 2
- 3
Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.